Volume 3.31 | Aug 17

Prostate Cell News 3.31 August 17, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY

Plk1 Is Upregulated in Androgen-Insensitive Prostate Cancer Cells and Its Inhibition Leads to Necroptosis
Scientists found that androgen-insensitive (AI) prostate cancer (PCa) cells are reprogrammed to upregulate the mitotic kinase polo-like kinase 1 (Plk1) and other M-phase cell-cycle proteins, which may underlie AI PCa growth. [Oncogene] Abstract

Detect 7 times more prostate epithelial progenitors with ProstaCult

PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Loss of pSer2448mTOR Expression Is Linked Adverse Prognosis and Tumor Progression in ERG-Fusion Positive Cancers
Investigators found that loss of pSer2448-mTOR staining was significantly linked to advanced stage, high-grade, nodal positive cancers, early tumor recurrence, lack of ERG-fusion, reduced AR expression, and increased cell proliferation in all cancers and in the subset of ERG-fusion positive cancers. [Int J Cancer] Abstract

PPARγ Isoforms Differentially Regulate Metabolic Networks to Mediate Mouse Prostatic Epithelial Differentiation
Researchers demonstrated control of overlapping and distinct aspects of prostate epithelial metabolism by ectopic expression of individual peroxisome proliferator-activated receptor gamma (γ) (PPARγ) isoforms in PPARγ knockout prostate epithelial cells. [Cell Death Dis] Full Article

Dynamic SUMOylation Is Linked to the Activity Cycles of Androgen Receptor in the Cell Nucleus
Researchers showed that androgen induces SUMO-2/3 modification (SUMOylation) of the endogenous androgen receptor in prostate cancer cells, which is also reflected in the chromatin-bound receptor. [Mol Cell Biol] Abstract

PAGE4 Positivity Is Associated with Attenuated Androgen Receptor Signaling and Predicts Patient Survival in Hormone-Naive Prostate Cancer
Scientists found that prostate-associated gene 4 (PAGE4) impaired the development of castration-resistant prostate cancer (PCa) xenografts, and strong PAGE4 immunoreactivity independently predicted favorable patient survival in hormone-naive PCa. [Am J Pathol] Full Article

Identification of CD166 as a Surface Marker for Enriching Prostate Stem/Progenitor and Cancer Initiating Cells
One of the best enrichment schemes for isolating the putative stem/progenitor cell from the murine prostate gland is Lin;Sca1+;CD49fhi. To further improve this enrichment scheme, investigators searched for cell surface molecules upregulated upon castration of murine prostate and identified CD166 as a candidate gene. [PLoS One] Full Article

FOXA1 Promotes Tumor Progression in Prostate Cancer via the Insulin-Like Growth Factor Binding Protein 3 Pathway
Scientists discovered that depletion of fork-head box protein A1 (FOXA1) in a prostate cancer cell line using small interfering RNA (siRNA) significantly inhibited androgen receptor activity, led to cell-growth suppression, and induced G0/G1 arrest. The anti-proliferative effect of FOXA1 siRNA was mediated through insulin-like growth factor binding protein 3. [PLoS One] Full Article

Embelin Inhibits Growth and Induces Apoptosis through the Suppression of Akt/mTOR/S6K1 Signaling Cascades
Researchers investigated the effects of embelin on the Akt/mTOR/S6K1 activation, associated gene products, cellular proliferation, and apoptosis in human prostate cancer cells. [Prostate] Abstract

Zoledronic Acid in Combination with Serine/Threonine Phosphatase Inhibitors Induces Enhanced Cytotoxicity and Apoptosis in Hormone-Refractory Prostate Cancer Cell Lines by Decreasing the Activities of Phosphatase 1 and Phosphatase 2A
Researchers investigated whether zoledronic acid induced growth inhibition and apoptosis in PC-3 and DU-145 may be enhanced by the combination with Calyculin A or Okadaic acid, through inhibition of serine/threonine phosphatases in prostate cancer cells. [BJU Int] Abstract

The Preventative Effects of Sunitinib Malate Observed in the Course from Non-Castration to Castration LNCaP Xenograft Prostate Tumors
Investigators evaluated the effect of the agent sunitinib malate in the course from non-castration to castration LNCaP xenograft prostate tumors. [J Cancer Res Clin Oncol] Abstract

CLINICAL RESEARCH

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Investigators evaluated whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy. [New Engl J Med]
Full Article | Press Release

Phase III Clinical Trial Investigating the Effect of Selenium Supplementation in Men at High-Risk for Prostate Cancer
Researchers investigated the effect of selenium supplementation on prostate cancer incidence in men at high risk for prostate cancer. [Prostate] Abstract

Rational Indication for Docetaxel Rechallenge in Metastatic Castration-Resistant Prostate Cancer
Scientists determined whether prostate-specific antigen (PSA) response at first-line chemotherapy with docetaxel correlates with PSA response and survival at docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer. [BJU Int] Abstract

[Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Watch Now.

INDUSTRY NEWS

Spectrum Pharmaceuticals Commences Patient Enrollment in Randomized Phase IIB Clinical Trial of Ozarelix for Hormone-Dependent Prostate Cancer
Spectrum Pharmaceuticals announced initiation of patient enrollment in the second part of the Company’s randomized phase II clinical program of ozarelix in men with prostate cancer for whom hormonal treatment is indicated. [Spectrum Pharmaceuticals, Inc.] Press Release


Wockhardt to Launch Generic Version of BPH Drug Uroxatral®

Wockhardt has received final approval from the United States Food & Drug Administration for marketing 10mg extended release tablets of Alfuzosin hydrochloride, which is used in treatment of benign prostatic hyperplasia (BPH) or enlarged prostate. [Wockhardt Limited] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Stem Cells Forum: Working Towards Clinical Application
October 3, 2012
Hertfordshire, United Kingdom

Visit our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Researcher – Transcriptomic Diagnostic for Prostate Cancer – (University of Leeds)

Postdoctoral Position – Prostate Cancer (BC Cancer Agency)

Postdoctoral Position – Prostate Cancer (Medical University of South Carolina)

Postdoctoral Position – Prostate Cancer Research (University of Texas Southwestern Medical Center)


Postdoctoral Position – Systems Biology in Prostate Cancer (Karolinska Institutet)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

 

Learn more about Prostate Cell News: Archives | Events | Contact Us